GRAIL (NASDAQ:GRAL) Shares Climb 6% – Should You Buy?

GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) was up 6% during trading on Thursday. The company traded as high as $110.59 and last traded at $108.2520. 110,969 shares were traded during trading, a decline of 88% from the average session volume of 961,897 shares. The stock had previously closed at $102.10.

Wall Street Analyst Weigh In

GRAL has been the topic of several research analyst reports. UBS Group increased their price target on shares of GRAIL from $105.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. Robert W. Baird upped their target price on shares of GRAIL from $96.00 to $118.00 and gave the company an “outperform” rating in a research report on Tuesday, September 22nd. Piper Sandler increased their price target on GRAIL from $74.00 to $130.00 and gave the company a “neutral” rating in a research note on Tuesday, November 10th. Morgan Stanley lifted their price objective on shares of GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Monday, October 12th. Finally, Guggenheim boosted their target price on GRAIL from $75.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $128.80.

Check Out Our Latest Stock Analysis on GRAL

GRAIL Stock Performance

The company has a fifty day moving average price of $122.99 and a two-hundred day moving average price of $79.79. The company has a market cap of $4.78 billion, a P/E ratio of -11.21 and a beta of 2.86.

GRAIL (NASDAQ:GRAL – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.45) by $0.24. The company had revenue of $37.53 million for the quarter, compared to analysts’ expectations of $44.21 million. GRAIL had a negative return on equity of 16.13% and a negative net margin of 243.80%. Research analysts anticipate that GRAIL, Inc. will post -9.11 EPS for the current year.

Insider Buying and Selling at GRAIL

In related news, insider Andrew Partridge sold 7,873 shares of GRAIL stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the completion of the sale, the insider owned 155,865 shares of the company’s stock, valued at approximately $22,817,077.35. The trade was a 4.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Joshua J. Ofman sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $136.85, for a total value of $2,737,000.00. Following the sale, the chief executive officer owned 342,271 shares of the company’s stock, valued at approximately $46,839,786.35. This represents a 5.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 132,944 shares of company stock worth $15,155,665 over the last 90 days. Company insiders own 1.83% of the company’s stock.

Hedge Funds Weigh In On GRAIL

Several institutional investors and hedge funds have recently modified their holdings of the business. Algert Global LLC acquired a new position in shares of GRAIL during the 3rd quarter worth approximately $1,742,000. Virtu Financial LLC acquired a new stake in GRAIL during the third quarter worth approximately $2,575,000. Sandler Capital Management acquired a new stake in GRAIL during the third quarter worth approximately $589,000. Quantitative Investment Management LLC bought a new position in GRAIL during the 3rd quarter worth $808,000. Finally, Aquatic Capital Management LLC bought a new position in GRAIL during the 3rd quarter worth $531,000.

GRAIL Company Profile

(Get Free Report)

GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.

Featured Stories

Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.